
There's no reason to be bitter about the plummeting share price of Israeli pharmaceutical company Teva, as it makes sense, according to CEO Kåre Schultz, who has not yet managed to generate value for the firm's hard-pressed shareholders.
"I'm alright with it. In my view, we've managed to save the company, reorganize it and bring down debts, but we're not done yet," says Schultz.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app